Provectus Biopharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Glass John R, was filed 18 Dec 2017.
Provectus Biopharmaceuticals, Inc.: what insiders have been doing
Provectus Biopharmaceuticals, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Provectus Biopharmaceuticals, Inc. The previous disclosure was published on 14 August 2024.
Our records for Provectus Biopharmaceuticals, Inc. go back to 2006, with 9 purchases and 26 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 336,108 USD and net income of -5.4 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- -9.4%Entry US$0.06 · Close at T+365 US$0.06
- -35.7%Entry US$2.55 · Close at T+365 US$1.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 264,314 shares@ US$2.86258.5% of flowSeries D-1 Convertible Preferred StockSEC:0001493152-24-032463:0
- 188,757 shares@ US$2.86241.5% of flowSeries D-1 Convertible Preferred StockSEC:0001493152-23-015964:0
- 800,000 shares0Common StockSEC:0001493152-20-021178:0
- 100,000 shares0Common StockSEC:0001493152-20-021179:0
- 50,000 shares0Common StockSEC:0001493152-20-021180:0
- 50,000 shares0Common StockSEC:0001493152-19-003976:0
- 115,900 shares@ US$0.05458.0% of flowCommon StockSEC:0000899243-17-028955:1Canonical exit: 14 Mar 2018 (T+90)
- 84,100 shares@ US$0.053942.0% of flowCommon StockSEC:0000899243-17-028955:0Canonical exit: 14 Mar 2018 (T+90)
- 100,000 shares@ US$1.25Common StockSEC:0000899243-16-017254:0
- 200,947 shares@ US$1.00Common StockSEC:0000899243-16-017257:0
- 106,000 shares@ US$1.00Common StockSEC:0000899243-16-017257:1
- 133,333 shares@ US$1.00Common StockSEC:0000899243-16-017260:0
- 27,333 shares@ US$1.00Common StockSEC:0000899243-16-017260:1
- 106,000 shares@ US$1.00Common StockSEC:0000899243-16-017260:2
- 120,000 shares@ US$1.02Common StockSEC:0001140361-15-045407:0
- 138,831 shares@ US$0.94Common StockSEC:0001140361-15-044135:0
- 6,383 shares@ US$0.94Common StockSEC:0001140361-15-044135:1
- 185,000 shares@ US$1.02Common StockSEC:0001140361-15-002672:0
- 76,764 shares@ US$0.64Common StockSEC:0001140361-15-000967:0
- 33,334 shares@ US$0.75Common StockSEC:0001140361-15-000969:0
- 29,786 shares@ US$0.94Common StockSEC:0001140361-15-000969:1
- 126,361 shares@ US$0.64Common StockSEC:0001140361-14-046713:0
- 96,875 shares@ US$0.64Common StockSEC:0001209191-14-065651:0
- 100,000 shares@ US$1.25Common StockSEC:0001140361-14-027129:0
- 25,000 shares@ US$0.95Common StockSEC:0001209191-14-035377:0
25 of 134 declarations
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer and skin diseases. The company is listed on NASDAQ under the symbol PVCT.
